Best Colon cancer doctors: TOP 121 doctors

One of the world-renowned pioneers in gastrointestinal surgery. Has developed new techniques for the colon and rectum cancer treatment TaTMEТ and NOTES — applied now around the world.
Has performed over 15,000 surgeries.
Performs over 1,000 interventions a year using minimally invasive techniques.
President of the Association of Surgeons-Endoscopists in Europe.

Specializations

Cancer Surgery

Pancreatic Surgery

Bile Duct Surgery

Bariatric Metabolic Surgery

Oncological Surgery

Breast Surgery

Gastric cancer

Colon cancer

Thyroid Cancer

Obesity Surgery

Diabetes Surgeries

Education

Ondokuz Mayıs University Faculty of Medicine (1991)

KTÜ Faculty of Medicine Farabi Hospital (Specialization.1998)

Istanbul University Çapa Faculty of Medicine (Laparoscopic Surgery Training, 2002)

Istanbul University Çapa Faculty of Medicine (Laparoscopic Antireflux Surgery Training, 2006)

Istanbul University Cerrahpaşa Faculty of Medicine (General Surgery Clinic Advance Laparoscopic Surgery, Laparoscopic Bariatric Surgery, Morbid Obesity and Oncological Cancer Surgery Training, 2010i)

Areas of Interests

• Breast cancer
• Lung cancer
• Colorectal cancers
• Gynecological and urogenital cancers
• Molecular Oncology

Education:

• Kızıltepe Anatolian High School 2001
• Dicle University Faculty of Medicine 2007
• Istanbul Medeniyet University Göztepe Training and Research Hospital 2014
• Kartal City Hospital 2021
• Associate Professor of Medical Oncology 2023

Experience:

• Liv Hospital Ulus
• Adıyaman University Training and Research Hospital
• Istanbul Umraniye Training and Research Hospital
• Istanbul Umraniye Training and Research Hospital

Research:

• Phase II, Randomized, Open-Label, Multicenter Study to Comparatively Evaluate the Efficacy and Safety of GDC-9545 and Physician-Preferred Endocrine Monotherapy in Previously Treated, Estrogen Receptor Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer Patients, Other ( International), Dr. Murat Ayhan
• Phase III, Randomized, Evaluating the Efficacy and Safety of Palbociclib and Fulvestrant with Gdc-0077 Compared with Placebo in Patients with Pik3ca-Mutant, Hormone Receptor-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer. Double Blind, Placebo Controlled Study, Other (International), Dr. Murat Ayhan
• Randomized, Multicenter, Phase Ib/III Study Evaluating the Pharmacokinetics, Efficacy, and Safety of Subcutaneous Atezolizumab Compared to Intravenous Atezolizumab in Patients with Previously Treated Locally Advanced or Metastatic Non-Small Cell Lung Cancer, Other (International) Dr. Murat Ayhan
• Randomized, Controlled, Multicenter, Open-Label Study Including Observation Follow-Up for PSMA-PET-Negative Patients, Investigating the Efficacy and Safety of Addition of Apalutamide to Radiotherapy and LHRH Agonist in PSMA-PET-Positive High-Risk Hormone-Sensitive Prostate Cancer Patients, Other (International) Dr. Murat Ayhan
• Biomarker Study to Identify Patients with Advanced Stage Urothelial Cancer and Fibroblast Growth Factor Receptor Gene Aberrations-42756493BLC0002, Other (International), Dr. Murat Ayhan
• Publications:
• Ayhan M, Turan N, Köstek O, et all. Does the efficacy of regorafenib differ in chemotherapy refractory metastatic colorectal cancer patients who had mucinous pathology compared to those who had non-mucinous pathology? Curr Probl Cancer. 2021 Jun;45(3):100670. doi: 10.1016/j.currproblcancer.2020.100670.
• Ayhan M, Odabas H, Turan N, et all. Factors affecting the mortality rate of patients with cancer hospitalized with COVID-19: a single center's experience. J Chemother. 2021 Nov;33(7):499-508. doi: 10.1080/1120009X.2021.1923153.
• Ayhan M, Laçin Ş, Özyükseler DT, et all. Does systemic anti-tumor therapy increase COVID-19 risk in patients with cancer? J Oncol Pharm Pract. 2021 Sep;27(6):1461-1467. doi: 10.1177/10781552211015762.
• Ayhan M, Abamor E, Coban Kokten S, et al. Value of FDG PET/CT in Predicting Pathologic Complete Response After Neoadjuvant Chemotherapy in Locally Advanced Breast Cancer. EJMI 2022;6(2):165–175.
• Ayhan M, Terzioglu K. Experience With Rapid Drug Desensitization With Chemotherapeutics; A SingleCentre Retrospective Study. EJMI 2021;5(3):380–387.
• Doğan A, AYHAN M. Survival analysis of patients with triple-negative breast cancer: a single-center experience. Journal of Oncological Sciences, 8(2), 94-99., Doi: 10.37047/jos.2022-89749
• Terzioğlu K, Ayhan M. Comparative Assessment of Platinum Salts and Taxane Group Hypersensitivity Reactions, The Role of Skin Tests in Diagnosis? J Oncol Pharm Pract. 2021 Nov 30:10781552211050084. doi: 10.1177/10781552211050084.
• Tacar SY, Selcukbiricik F, Yilmaz M, Erturk K, Murat Sarici A, Gulturk I, Ayhan M, Tural D. Nivolumab for metastatic uveal melanoma: a multicenter, retrospective study. Melanoma Res. 2021 Oct 1;31(5):449-455. doi: 10.1097/CMR.0000000000000744.
• Özyurt E, Özçelik S, Sürmeli H, Çelik M, Ayhan M, Özçelik M. Side effects of immune-checkpoint inhibitors: Can multiple side effects be seen in a patient? J Oncol Pharm Pract. 2022 Mar;28(2):462-465. doi: 10.1177/10781552211038136.
• Dülgar Ö, Öven BB, Atcı MM, Arıkan R, Ay S, Ayhan M, Selvi O, Ozyukseler DT, Bayram E, Özcan E, Yasin Aİ, Gümüş M. Is the benefit of using adjuvant capecitabine in patients with residual triple-negative breast cancer related to pathological response to neoadjuvant chemotherapy? Expert Rev Anticancer Ther. 2022 Jul;22(7):773-780. doi: 10.1080/14737140.2022.2076670.
• Hizal M, Bilgin B, Paksoy N, Ayhan M, et all. The real-life efficacy and safety of osimertinib in pretreated advanced non-small cell lung cancer patients with T790M mutation: a Turkish Oncology Group Study. J Cancer Res Clin Oncol. 2022 Jun;148(6):1501-1508. doi: 10.1007/s00432-021-03748-7.
• Volume I, Kucukarda A, Atcı MM, Ayhan M, et all. Efficacy and safety of trastuzumab emtansine in older patients with HER2-positive advanced breast cancer: a real-world study. Tumori. 2022 Feb;108(1):19-25. doi: 10.1177/03008916211037739.
• Dogan I, Ayhan M, Gurbuz M, et all. The frequency and prognostic significance of ABO/Rh blood groups in male breast cancer patients: A multicenter study. Medicine (Baltimore). 2022 Sep 2;101(35):e30147. doi: 10.1097/MD.0000000000030147.
• Ozcelik M, Oyman A, Cil I, Duzgun O, Ozkan OF, Ayhan M. Cytoreductive Surgery versus Systemic Chemotherapy alone in Isolated Peritoneal Carcinomatosis of Colorectal Origin. J Coll Physicians Surg Pak. 2021 Nov;31(11):1308-1313. doi: 10.29271/jcpsp.2021.11.1308.
• Başoğlu T, Sakin A, Erol C, Ayhan M, et all. Real life experienceof patients with locally advanced gastric and gastroesophageal junction adenocarcinoma treated with neoadjuvant chemotherapy: a Turkish oncology group study. J Chemother. 2022 May 17:1-8. doi: 10.1080/1120009X.2022.2073159.
• Özdemir Ö, Zengel B, Yildiz Y, Ayhan M, et all. The effectiveness and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early-stage human epidermal growth factor receptor 2-positive breast cancer: Turkish Oncology Group study. Anticancer Drugs. 2022 Aug 1;33(7):663-670. doi: 10.1097/CAD.0000000000001310.
• Hizal M, Bilgin B, Paksoy N, Ayhan M, et all. The percentage of ALK-positive cells and the efficacy of first-line alectinib in advanced non-small cell lung cancer: is it a novel factor for stratification? (Turkish Oncology Group Study). J Cancer Res Clin Oncol. 2022 Sep 1. doi: 10.1007/s00432-022-04252-2.
• Hizal M, Bilgin B, Paksoy N, Ayhan M, et all. Real-world data on efficacy and safety of first-line alectinib treatment in advanced-stage, ALK-positive non-small-cell lung cancer patients: a Turkish Oncology Group study. Future Oncol. 2022 Jul;18(23):2573-2582. doi: 10.2217/fon-2022-0083.
• Topcu A, Atci MM, Secmeler S, Besiroglu M, Ayhan M, Ozkan M, Bozkurt O, Urakci Z, Ay S, Geredeli C, Yasin AI, Turk HM. Efficacy of trastuzumab and potential risk factors on survival in patients with HER2-positive metastatic gastric cancer. Future Oncol. 2021 Nov;17(31):4157-4169. doi: 10.2217/fon-2021-0398.
• Bilgin B, Sendur MAN, Yucel S, Ayhan M, et all. Real-life comparison of the afatinib and first-generation tyrosine kinase inhibitors in nonsmall cell lung cancer harboring EGFR exon 19 deletion: a Turk Oncology Group (TOG) study. J Cancer Res Clin Oncol. 2021 Jul;147(7):2145-2152. doi: 10.1007/s00432-020-03501-6.
• Atci MM, Akagunduz B, Demir M, Arikan R, Ay S, Ozer M, Ayhan M, Cil I, Demir N, Ozyurt N, Karakaya G, Cevik GT, Onder AH, Selvi O, Sakin A. The impact of adjuvant oxaliplatin and tumor sidedness on the overall survival of stage IIB colon cancer patients: a multicentre study. J Chemother. 2023 Feb;35(1):19-28. doi: 10.1080/1120009X.2022.2040770.
• Tataroglu Ozyukseler D, Ay S, Turan M, Alkan G, Ayhan M, Surmeli H, et al. The Systemic Inflammation Response Index as a Prognostic Marker in Advanced Pancreatic Cancer. EJMI 2022;6(3):367–373.
• Yıldız F, Ayhan M, Demir H, et all. Comparing the efficacy of cabazitaxel in secondline and third-Line treatment of metastatic castration-resistant prostate cancer: a multi-center experience from Turkey. International Journal of Contemporary Medical Research, 7(9), 112-116.,Doi: 10.21276/ijcmr.2020.7.9.30
• Terzioğlu K, Ayhan M. Distribution of allergens detected on patch tests of patients with allergic contact dermatitis and investigation of their atopic background. Annals of Medical Research, 29(5), 422-426., doi: 10.5455/annalsmedres.2021.07.490
• Arikan R, Atci MM, Ay S, Ayhan M, et all Prognostic significance of mucinous histology in left sided metastatic colorectal cancers with wild type RAS and evaluation of backbone chemotherapy regimens. Oncol Lett. 2023 Apr 5;25(5):208. doi: 10.3892/ol.2023.13795.
• Almuradova E, Yalcin S, Arıkan R, Ayhan M, Demir H, Cevik GT, Karaca M, Petekkaya I, Karabulut B. Survival of Patients With Metastatic Rectum Cancer Who Underwent Metastasectomy Following Conversion Chemotherapy Sans Pelvic Radiotherapy: A Turkish Oncology Group Study. Cureus 2023 May 17;15(5):e39119. doi: 10.7759/cureus.39119.
• Topcu A, Besiroglu M, Atci MM, Ayhan M, et all. Second-line Therapy after Trastuzumab Failure in HER2-Positive Metastatic Gastric Cancer: A Real-life Data. EJMI 2023;7(2):153–161. DOI: 10.14744/ejmi.2023.22720
• Book Writing:
• Drug interactions and side effects of targeted agents, Section name: (Small molecule tyrosine kinase inhibitors; ROS-1 targeted therapies (Crizotinib, Seritinib)) (2021)., AYHAN MURAT, Turkish Clinics Journal of Medical Sciences, Editor: Mehmet Aliustaoglu, Publishing number:1, Number of Pages 92, ISBN:978-625-401- 466-6, Turkish
• Approach to gastrointestinal stromal tumors and neuroendocrine tumors, Department name: (Medical approach in primary non-gastrointestinal neuroendocrine tumors) (2020)., AYHAN MURAT, Akademisyen Yayınevi, Editor: Anılır Ender, Number of editions: 1, Number of Pages 382, ISBN: 9786052585719, Turkish
• Internal medicine emergencies, Department name: (Oncological emergencies) (2022)., YILDIRIM SEDAT, AYHAN MURAT, Efe Academic Publishing, Editor: Serdar Olt, Number of editions: 1, Number of Pages 232, ISBN: 978-625-8324-66- 2, Turkish
• Physicians' chemotherapy cancer drug manual 2020, Section name: (Common chemotherapy regimens in clinical practice) (2022)., SÜMBÜL AHMET TANER, ALKAN ALI, AKSOY ASUDE, AYHAN MURAT, et all, Türkiye Klinikleri Journal of Medical Sciences, Editor: EDWAR CHU, VINCENT T. DEVITA, SAADDETIN KILIÇKAP, CEMIL BILIR, SELÇUK SEBER, Number of editions: 1, Number of pages 772, ISBN: 978-625-401-290- 7, Turkish (Book Translation)

Chief Physician of the Oncology Center, Oncologist

Professor, specialist in endocrinology

Prof. Moshe Inbar is an Israeli oncologist and the Head of Department of Oncology at Sourasky (Ichilov) Medical Center, specializing in breast cancer, cancer of the uterus and ovaries, urogenital cancer in female and male, and gastro-intestinal cancer. He is a Clinical Associate Professor in Tel Aviv University, holds numerous awards and is a member of various research organizations.

Dr. Tamar Jablonski-Perec is an oncologist at Hadassah Medical Center in Jerusalem. She holds a Doctor of Medical Sciences from the Hebrew University and has experience from the renowned Sloan-Kettering Cancer Center in New York. She is the Head of Institute of Oncology, Head of Breast Cancer Treatment Center, and Professor of the Department of Oncology at the Hebrew University. She is a member of several international cancer communities and was awarded a scholarship from the Hadassah Medical School.

Dr. Alexander Beny is a Oncologist at the Rambam Medical Center who is Board Certified in Oncology and speaks English and Hebrew. He has extensive experience and education in the field and is available for contact at the hospital.

Medical Interests and Activities 

• Gastrointestinal diseases 

• Oncologic laparoscopic surgery 

• Anorectal area diseases 

• Urgent surgical cases (acute cholecystitis, divertikülit, ileus, pankreatit, appendicitis) 

• Colon and rectum cancer 

• Treatment of oncologic surgical cases with further laparoscopic and robotic surgery. • Laparoskopik hernia surgery 

• Esophagus and stomach cancer 

• Selim anorectal diseases (hemorrhoidal disease, anal fissure), perianal fistula, pilonoidal sinus (hairless- non-surgical treatment)

Education and Experience 

• İstanbul University Medical Faculty 1988 • University of Colorado Health Science Center – Intern Surgeon 

• Isparta, Dedeçam Şehit Ramazan Karaca Health Center (1995-1996) • İstanbul Surgery Hospital – American Hospital (2000-2001) 

• Chief assistant Istanbul Medical Faculty, Department of General Surgery (2001-2008) • World Congress on Peritonel Surface Malignancies (HIPEC course) Berlin, Germany (2012) 

• USC Keck School of Medicine, Los Angeles, CA, USA (2006-2007) 

• Assoc. Prof. M.D. , İstanbul Medical Faculty General Surgery (2008-2014) 

• Da Vinci Robotic Intensive Course at IRCAD, Strasbourg, France (2011) 

• Stony Brook Medicine Cadaver Training Event in Colon and Rectal Surgery, New York, USA (2016) (Instructor) 

• Fellow of the European Board of Surgery- Emergency Surgery (FEBS EmSurg) Honorary Diploma (2017) 

• Prof. M.D. , İstanbul Medical Faculty General Surgery (2014 -2017) 

• İstanbul University Medical Faculty – General Surgery Master of Science 1996 

• University of Southern California Medical Center, Department of General Surgery, Los Angeles, USA – February 2006 – February 2007

Scientific Publications • Endoscopic Laparoscopic & Minimal Invasive Surgery Journal Editorial Board / National Scientific Committee • UTACD Assist. Editor

Deputy Head of the Department of Oncology. One of the leading Israeli specialists in the digestive tract tumors, sarcoma and melanoma

Dr. Alon Pikarsky is a board-certified general and colorectal surgeon at Hadassah Medical Center. He received his Israel Board Certification in General Surgery in 1998. He has led the Medical Students Program in Surgery since 1997. Since 2000, he has also served as Residency Program Director.

Dr. Pikarsky is known for his academic leadership. He has worked as an instructor in surgery since 1995, a lecturer since 1999, and a senior lecturer since 2005. He is an active member of several surgical associations. Dr. Pikarsky speaks both English and Hebrew fluently.

Diseases

• Lung Cancer
• Skin Cancers
• Gastrointestinal Cancers
• Genitourinary Cancers
• Gynecological Cancers
• Colon Cancer
• Breast Cancer
• Rare Cancers

Treatment Methods

• Individual Treatments (Comprehensive Genomic Profiling)
• Targeted Therapies
• Immunotherapy
• Cancer Vaccines
• Chemotherapy
• Clinical Research/Experimental Medical Research

Experience

• 2017- 2024: Katip Çelebi University Faculty of Medicine Atatürk Education and Research Hospital Medical Oncology Clinic Associate Professor / Lecturer
• 2022 December – 2023 March: Academic visitor Moffitt Cancer Center Cutaenous Oncology Clinic Tampa, Florida USA
• 2013- 2017: Katip Çelebi University Faculty of Medicine Atatürk Training and Research Hospital – Medical Oncology Clinic Specialist Physician
• 2012-2013: Izmir Education and Research Hospital, Medical Oncology Specialist Physician
• 2012-2012: Mersin State Hospital, Medical Oncology Specialist Physician
• 2010-2012: Dokuz Eylül University Faculty of Medicine, Department of Medical Oncology, Sub-branch Research Assistant
• June-August 2008, December 2008 – February 2009: Memorial Sloan Kettering Cancer Center Observership programme
• 2007-2009: Kartal Education and Research Hospital, Medical Oncology Sub-branch Research Assistant
• 2006-2007: Siirt State Hospital, Internal Medicine, Specialist Physician
• 2005-2006: Çukurova University Faculty of Medicine, Medical Oncology Sub-branch Research Assistant
• 2004-2005: SSK Siirt Hospital, Internal Medicine Specialist Physician
• 2003-2004: SSK Mardin Hospital, Internal Medicine Specialist Physician
• 1998-2003: SSK Izmir Training and Research Hospital, 3rd Internal Medicine Clinic, Research Assistant
• 1998-1998: SSK Izmir Training and Research Hospital Infectious Diseases Research Assistant
• 1997-1998: Izmir Ataturk Training and Research Hospital, Anesthesiology and Reanimation Clinic, Research Assistant
• 1995-1997: Şırnak Cizre Central Health Center
• 1994-1995: Şırnak İdil Oyalı Village Health Center

Professional Memberships

• Turkish Society of Medical Oncology 2008 
• (2018-2021 Term Board Member)
• Izmir Oncology Group, Board Member (2014 -…)
• Geriatric Oncology Association, Board Member (2015-…)
• Mediterranean Oncology Association Board Member (2020 -…)
• Turkish Biochemistry Association, Member, 2016
• European Society of Medical Oncology, Member, 2012
• American Society of Clinical Oncology, Member, 2008

Professor Kyu Taek Lee is a top gastroenterologist from South Korea, specializing in the management of pancreatic, bile duct and gallbladder cancers. He is a Gastroenterology specialist at Samsung Medical Center and has degrees from Hanyang University College of Medicine, Stanford University School of Medicine, and Kyoto Second Red Cross Hospital. He is also a member of The Korean Society of Gastrointestinal Endoscopy and The Korean Society of Gastroenterology.

Prof. Jong Kyun Lee is a highly experienced gastroenterologist specializing in the management of pancreatic, bile duct and gallbladder cancers, pancreatitis, and gallstones. He has worked at Samsung Medical Center and holds degrees from the Seoul National University College of Medicine and the University of California. He is a member of several organizations, including The Korean Society of Gastrointestinal Endoscopy, The Korean Society of Gastroenterology, and The Korean Pancreatobiliary Association.

Dr. Joseba Rebollo Liceaga is a seasoned medical oncologist with a comprehensive background in oncology.​

Education and Training:

Graduated in Medicine and Surgery from the University of Navarra (1985).​

Completed residency in Oncology in 1987.​

Specialist in Medical Oncology at the Clínica Universidad de Navarra (1991).​

Professional Experience:

Head of the Oncology Department at Clínica San Miguel de Navarra (1991–2004).​

Associate Physician at the University Clinic of the Faculty of Medicine, University of Navarra (1995–2002).​

Adjunct Physician at the Oncology Platform, Hospital Quirónsalud Torrevieja (2004–2014).

Head of the Oncology Department at Hospital General de Villalba (2014–2019).​

Currently practices as a Medical Oncology Specialist at Quirónsalud Alicante.​

Certifications and Training:

Completed multiple accredited courses in Multidisciplinary Oncology between 2003 and 2006.​

Research and Publications:

Authored research on electrochemotherapy and multidisciplinary treatment approaches in oncology.